DelveInsight’s “Central Nervous System Tumors Pipeline Insight 2025” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Central Nervous System Tumors pipeline landscape. It covers the Central Nervous System Tumors pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Central Nervous System Tumors Pipeline. Dive into DelveInsight’s comprehensive report today! @ Central Nervous System Tumors Pipeline Outlook

Key Takeaways from the Central Nervous System Tumors Pipeline Report

• In May 2025, Genmab announced a study will be conducted in two parts: Part 1 (dose-finding) and Part 2 (randomization). The main purpose is to assess the safety and clinical activity of GEN1042 in combination with radiotherapy or GEN1042 in combination with radiotherapy and pembrolizumab as a treatment option for participants with metastatic solid tumors.
• In May 2025, Stemline Therapeutics Inc. announced a study that includes a phase 1b evaluation of elacestrant in combination with abemaciclib in women and men with brain metastases from estrogen receptor (ER)-positive, human epidermal growth factor receptor-2 (HER-2) negative breast cancer. Phase 1b was designed to select the recommended phase 2 dose and is followed by an ongoing phase 2 evaluation of elacestrant in combination with abemaciclib in patients with active brain metastases from ER-positive, HER-2 negative breast cancer.
• In May 2025, Hoffmann-La Roche organized a study will evaluate the safety, pharmacokinetics, and efficacy of alectinib in children and adolescents with ALK fusion-positive solid or CNS tumors for whom prior treatment has proven to be ineffective or for whom there is no satisfactory standard treatment available.
• DelveInsight’s Central Nervous System Tumors Pipeline report depicts a robust space with 13+ active players working to develop 13+ pipeline therapies for Central Nervous System Tumors treatment.
• Promising Central Nervous System Tumors Companies such as Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others.
• The leading Central Nervous System Tumors Pipeline Therapies such as Tozuleristide, Bevacizumab, Temozolomide, Pomalidomide, Niraparib, GNC-038, Pamiparib, Thalidomide and others.

Stay ahead with the most recent pipeline outlook for Central Nervous System Tumors. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Central Nervous System Tumors Treatment Drugs

Central Nervous System Tumors Emerging Drugs Profile

• F520: Shandong New Time Pharmaceutical

F 520 is a humanized monoclonal antibody targeting programmed cell death 1 receptor antagonists being developed by Shandong New Time Pharmaceutical. The drug is being investigated in Phase II stage of development for the treatment of patients with Primary and secondary Central Nervous System Lymphoma.

• Tirabrutinib: Ono Pharmaceuticals

Velexbru, discovered and developed by ONO, is a highly selective, oral BTK inhibitor and has been developed for the treatment in patients with B-cell tumors and autoimmune diseases in Japan. B-cell receptor (BCR) signaling plays a core role in the survival, activation, proliferation, maturation and differentiation of B-cell lymphocyte. In Japan, Velexbru was approved in March 2020 and launched in May 2020 for the treatment of relapsed or refractory primary central nervous system lymphoma (PCNSL). Ono Pharmaceutical has initiated a Phase II clinical trial in US with Velexbru in patients with primary central nervous system lymphoma.

The Central Nervous System Tumors Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Central Nervous System Tumors with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Central Nervous System Tumors Treatment.
• Central Nervous System Tumors Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Central Nervous System Tumors Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Central Nervous System Tumors market

Explore groundbreaking therapies and clinical trials in the Central Nervous System Tumors Marketed and Pipeline Drugs. Access DelveInsight’s detailed report now! @ New Central Nervous System Tumors Drugs

Central Nervous System Tumors Companies

Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others.

Central Nervous System Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical
• Molecule Type

Central Nervous System Tumors Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Unveil the future of Central Nervous System Tumors Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Central Nervous System Tumors Market Drivers and Barriers

Scope of the Central Nervous System Tumors Pipeline Report

• Coverage- Global
• Central Nervous System Tumors Companies- Shandong New Time Pharmaceutical, PIQUR Therapeutics, Ono Pharmaceutical, Janssen, LP, Kazia Therapeutics, Beijing InnoCare Pharma Tech, Celltrion, Bristol Myers Squibb, AstraZeneca, Novartis, Prelude Therapeutics, Kite, A Gilead Company, Celgene and others.
• Central Nervous System Tumors Pipeline Therapies- Tozuleristide, Bevacizumab, Temozolomide, Pomalidomide, Niraparib, GNC-038, Pamiparib, Thalidomide and others.
• Central Nervous System Tumors Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Central Nervous System Tumors Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Central Nervous System Tumors Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Central Nervous System Tumors Companies, Key Products and Unmet Needs

Table of Contents

1. Introduction
2. Executive Summary
3. Central Nervous System Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Drug Name: Company Name
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. F520: Shandong New Time Pharmaceutical
11. Drug profiles in the detailed report…..
12. Early stage products (Phase I)
13. PRT811: Prelude Therapeutics
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Central Nervous System Lymphoma Key Companies
17. Central Nervous System Lymphoma Key Products
18. Central Nervous System Lymphoma- Unmet Needs
19. Central Nervous System Lymphoma- Market Drivers and Barriers
20. Central Nervous System Lymphoma- Future Perspectives and Conclusion
21. Central Nervous System Lymphoma Analyst Views
22. Central Nervous System Lymphoma Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/central-nervous-system-lymphoma-pipeline-insight